Pfizer (NYSE:PFE) Releases Earnings Results, Beats Estimates By $0.08 EPS

Pfizer (NYSE:PFE) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08, Zacks reports. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer updated its FY 2025 guidance to 3.000-3.150 EPS.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.14 during midday trading on Wednesday, reaching $24.44. The company had a trading volume of 45,011,211 shares, compared to its average volume of 48,580,551. The business’s 50-day simple moving average is $24.75 and its 200 day simple moving average is $24.33. The stock has a market cap of $138.93 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer has a 1 year low of $20.92 and a 1 year high of $27.99. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the second quarter worth $32,000. WFA of San Diego LLC purchased a new position in shares of Pfizer during the second quarter worth $40,000. WealthCollab LLC raised its holdings in shares of Pfizer by 12.5% during the second quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 442 shares during the last quarter. Binnacle Investments Inc raised its holdings in shares of Pfizer by 65.1% during the second quarter. Binnacle Investments Inc now owns 5,752 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 2,267 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Pfizer by 77.8% during the second quarter. State of Wyoming now owns 7,427 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 3,251 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFE. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.